Nykode Therapeutics AS (CHIX:NYKDO) Marketable Securities: kr0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:NYKDO Nykode Therapeutics AS CHIX:NYKDO
49 GF Score
Price kr18.69
GF Value kr28.04
! 3 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Marketable Securities?

Nykode Therapeutics AS CHIX:NYKDO 49 Marketable Securities is kr0.00 Mil as of Jun. 2026. GuruFocus rates CHIX:NYKDO with a GF Score™ of 49/100 and a GF Value™ of kr28.04. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Nykode Therapeutics AS's Marketable Securities for the quarter that ended in Jun. 2026 was kr0.00 Mil.

Nykode Therapeutics AS  (CHIX:NYKDo) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Nykode Therapeutics AS Marketable Securities Related Terms

Nykode Therapeutics AS Marketable Securities Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Marketable Securities Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 109.29 0.00 0.00 0.00 0.00

Nykode Therapeutics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:NYKDO
49GF Score
Nykode Therapeutics AS CHIX:NYKDO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr0.00 Mil mean?
Nykode Therapeutics AS (CHIX:NYKDO) has a Marketable Securities of kr0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Marketable Securities too high?
Nykode Therapeutics AS's current Marketable Securities is kr0.00 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Marketable Securities compare to VRTX and REGN?
Nykode Therapeutics AS's Marketable Securities of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Marketable Securities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Nykode Therapeutics AS (CHIX:NYKDO) has a current Marketable Securities of kr0.00 Mil. The stock's GF Value™ is kr28.04, compared to a current price of kr18.69 — trading 33.3% below its estimated fair value. The current Marketable Securities is kr0.00 Mil. Nykode Therapeutics AS's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Nykode Therapeutics AS (CHIX:NYKDO), the current Marketable Securities is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (CHIX:NYKDO) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of kr18.69 is trading 33.3% below its estimated GF Value™ of kr28.04.

Key valuation signals for CHIX:NYKDO:

  • Marketable Securities: kr0.00 Mil
  • GF Value™: kr28.04 vs. price of kr18.69 (33.3% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the CHIX:NYKDO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
49GF Score

Get the complete analysis for CHIX:NYKDO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.69
Price
kr28.04
GF Value